Frontiers in Anti-Cancer Drug Discovery

Volume 4

by

Atta-ur-Rahman , M. Iqbal Choudhary

DOI: 10.2174/9781608592251140401
eISBN: 978-1-60805-922-5, 2014
ISBN: 978-1-60805-923-2
ISSN: 1879-6656 (Print)



Recommend this eBook to your Library

Indexed in: Scopus, EMBASE

Frontiers in Anti-Cancer Drug Discovery is an Ebook series devoted to publishing the latest and the most important ad...[view complete introduction]

Table of Contents

Preface

- Pp. i-ii (2)

Atta-ur-Rahman and M. Iqbal Choudhary

Download Free

List of Contributors

- Pp. iii-vi (4)

Atta-ur-Rahman and M. Iqbal Choudhary

Download Free

Substance P, the NK-1 Receptor and NK-1 Receptor Antagonists in Cancer Treatment

- Pp. 3-38 (36)

Miguel Muñoz and Rafael Coveñas

View Abstract Purchase Chapter

Molecular Targeted Drugs under Investigation in Hepatocellular Carcinoma

- Pp. 39-87 (49)

Mohamed Bouattour and Johanna Wassermann

View Abstract Purchase Chapter

Ruthenium Compounds Targeting Cancer Therapy

- Pp. 88-156 (69)

Denise de Oliveira Silva

View Abstract Purchase Chapter

Molecularly-Targeted Therapeutic Strategies for Breast Cancer Focusing on HER2-Targeted Therapy, mTOR Inhibitor and Antiangiogenic Therapy

- Pp. 157-228 (72)

Teruhiko Fujii, Keisuke Miwa, Tomoyuki Ushijima, Mototsugu Matsunaga, Masaru Fukahori, Kotaro Yuge, Uhi Toh, Nobutaka Iwakuma, Ryuji Takahashi, Hiroki Takahashi, Miki Takenaka, Mai Mishima, Yoshito Akagi, Masayoshi Kage, Shino Nakagawa and Maki Tanaka

View Abstract Purchase Chapter

Purinergic Modulation and CD39/ENTPD1 in Cancer

- Pp. 229-292 (64)

Lili Feng, Elliot B. Tapper, Xiaofeng Sun, Marina Gehring, Simon C. Robson and Yan Wu

View Abstract Purchase Chapter

HER2 Targeted Monoclonal Antibodies and Tyrosine Kinase Inhibitors

- Pp. 293-382 (90)

Neil A. O`Brien, Alexandra Canonici, Karen Howe, Martina S.J. McDermott, Denis M. Collins, Brigid C. Browne, John Crown and Norma O`Donovan

View Abstract Purchase Chapter

Index

- Pp. 383-405 (23)

Atta-ur-Rahman and M. Iqbal Choudhary

Download Free

Preface

Development of safe and effective anti-cancer drugs is one the most active areas of scientific research today and it is likely to remain so for years to come. Cancers cause more deaths than any other single disease, both in the developed and developing world. Prognosis in many forms of cancers is often glimpsed, despite major development in surgery and radiotherapy. Development of cancer chemotherapy remains an important challenge. The major bottleneck in the development of safe and effective anti-cancer drugs is the complex nature of the disease, involving still far from perfect understanding of the disease process at the molecular level, heterogeneity, and environmental factors. Emergence of resistance against existing drugs is yet another challenge to be faced.

Research and development in the area of anti-cancer therapies are overwhelming. For researchers working in this field, it is often difficult to keep track of and benefit from the key developments. The eBook series, Frontiers in Anti-Cancer Drug Discovery, is intended to represent the most notable developments in the field in the form of cutting edge reviews written by the leading experts.

Volume 4 of the eBook series, Frontiers in Anti-Cancer Drug Discovery, is a compilation of six well written and well referenced chapters contributed by some of the most prominent researchers in the field of cancer chemotherapy. Munoz and Coveas skillfully review the role of peptide substance P (SP), and the NK-1 receptor in cancer progression, especially migration of tumor cells, angiogenesis and antiapoptotic effects. Based on this, they have discussed the relevance of NK-1 receptor antagonists in blocking the function of SP, thus serving as Intelligent Bullets against cancer.

Bouattour and Wassermann have contributed a review on the understanding of the hepatocellular carcinoma (HCC) at the molecular level, and identification of targets for drug development against this orphan disease. Angiogenesis plays an important role in the progression of HCC due to the well-vascularized nature of the tumor. They review the results of pre-clinical and clinical studies on some novel agents against HCC targeting angiogenesis.

Metal complexes play an important role in cancer chemotherapy. The best known example is cisplatin. However, platinum based drugs are known for severe adverse effects, lack of tolerability and emerging resistance. Oliveira Silva reviews the anticancer and antitumor activities of ruthenium based drugs against cancer. Several of these complexes have entered into clinical trials and have shown great promise.

Fujii et al. have contributed a comprehensive review on the development of chemotherapy or endocrine therapy against breast cancer. The overall theme is the effectiveness of molecularly-targeted therapy. These therapies exert their effects anticancer/anti-tumor effects by targeting human epidermal growth factor receptor (HER), mammalian target of rapamycin (mTOR) and vascular endothelial growth factor (VEGF).

Wu et al. review the role of intracellular signaling transduction pathways (Purinergic signaling) in cancer and associated inflammation and immune response. Recent advances in the development of purinergic modulators as cancer therapies have also been comprehensively discussed.

Last but not the least, the role of HER2 (Human epidermal growth factor receptor 2) in breast cancer is extensively reviewed by ODonovan et al. HER2 is over-expressed in breast cancer, particularly in aggressive types. In the last decade, the HER2 has been a popular target for the development of breast cancer therapies. Some of these drugs, along with their mechanisms of action, limitations and effectiveness in various stages of breast and other cancers are discussed in this article.

This volume of the eBook series represents the results of a considerable amount of work by many eminent contributors. We wish to thank them all for their excellent contributions and their commitment to complete the writing assignments in time. We would also like to thank the excellent team of the Bentham Science Publishers, especially Ms. Fariya Zulfiqar. The team is led by Mr. Mahmood Alam, Director Bentham Science Publishers, who deserves all appreciation.

Prof. Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
UK

Prof. M. Iqbal Choudhary
H.E.J. Research Institute of Chemistry
International Center for Chemical and Biological Sciences
University of Karachi
Pakistan


List of Contributors

Editor(s):
FRS Atta-ur-Rahman
University of Cambridge
Kings College
Cambridge
UK


M. Iqbal Choudhary
Biological Sciences
H.E.J. Research Institute of Chemistry
University of Karachi
Karachi, 75270
Pakistan




Contributor(s):
Alexandra Canonici
National Institute for Cellular Biotechnology
Dublin City University
Ireland


Brigid C. Browne
The Kinghorn Cancer Centre
Garvan Institute of Medical Research
Sydney
Australia


Denis M. Collins
National Institute for Cellular Biotechnology
Dublin City University
Ireland


Denise de Oliveira Silva
Department of Fundamental Chemistry
Institute of Chemistry, University of São
Paulo, Av. Prof. Lineu Prestes, 748,
São Paulo
SP, 05508-000
Brazil


Elliot B. Tapper
Division of Gastroenterology, Department of Medicine
Beth Israel Deaconess Medical Center, Harvard Medical School
Boston
MA
USA


Hiroki Takahashi
Department of Surgery
Kurume University
Kurume
Japan


Johanna Wassermann
Department of Medical Oncology,
La Pitié Salpêtrière University Hospital
Assistance Publique-Hôpitaux de Paris
Paris
France


John Crown
National Institute for Cellular Biotechnology
Dublin City University
St. Vincent’s University Hospital
Dublin
Ireland


Karen Howe
National Institute for Cellular Biotechnology
Dublin City University,
Ireland


Keisuke Miwa
Multidisciplinary Cancer Treatment Center
Kurume University
Kurume
Japan


Kotaro Yuge
Multidisciplinary Cancer Treatment Center,
Kurume University
Kurume,
Japan


Lili Feng
Division of Gastroenterology, Department of Medicine
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston
MA
USA
/
Department of Hematology
Provincial Hospital Affiliated to Shandong University
Jinan
P.R.
China


Mai Mishima
Department of Surgery
Kurume University
Kurume
Japan


Maki Tanaka
Kurume General Hospital
Kurume
Japan


Marina Gehring
Division of Gastroenterology, Department of Medicine
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston
MA
USA


Martina S.J. McDermott
Department of Drug Discovery and Biomedical Sciences
South Carolina College of Pharmacy
University of South Carolina
Columbia


Masaru Fukahori
Multidisciplinary Cancer Treatment Center
Kurume University
Kurume
Japan


Masayoshi Kage
Center for Innovative Cancer Therapy
Kurume University
Kurume
Japan
/
Department of Pathology
Kurume University
Kurume
Japan


Miguel Muñoz
Research Laboratory on Neuropeptides (IBIS)
Virgen del Rocío University Hospital
Sevilla
Spain


Miki Takenaka
Department of Surgery
Kurume University,
Kurume
Japan


Mohamed Bouattour
Department of Hepatology
Beaujon University Hospital
Assistance Publique-Hôpitaux de Paris,
Paris
France


Mototsugu Matsunaga
Multidisciplinary Cancer Treatment Center
Kurume University
Kurume
Japan


Neil A. O’Brien
Department of Medicine
Division of Hematology/Oncology
Geffen School of Medicine at UCLA
Los Angeles
CA
USA


Nobutaka Iwakuma
Department of Surgery
Kurume University
Kurume
Japan


Norma O’Donovan
National Institute for Cellular Biotechnology
Dublin City University
Ireland


Rafael Coveñas
Laboratory of Neuroanatomy of the Peptidergic Systems (Lab. 14)
Institute of Neurosciences of Castilla y León (INCYL)
University of Salamanca
Salamanca
Spain


Ryuji Takahashi
Department of Surgery
Kurume University
Kurume
Japan


Shino Nakagawa
National Hospital Organization Kyushu Medical Cancer
Breast Care Center
Clinical Research Institute
Fukuoka
Japan


Simon C. Robson
Division of Gastroenterology, Department of Medicine
Beth Israel Deaconess Medical Center, Harvard Medical School
Boston
MA
USA


Teruhiko Fujii
Multidisciplinary Cancer Treatment Center
Kurume University
Kurume
Japan
/
Center for Innovative Cancer Therapy,
Kurume University
Kurume
Japan


Tomoyuki Ushijima
Multidisciplinary Cancer Treatment Center
Kurume University
Kurume
Japan


Uhi Toh
Department of Surgery
Kurume University
Kurume
Japan


Xiaofeng Sun
Division of Gastroenterology, Department of Medicine
Beth Israel Deaconess Medical Center, Harvard Medical School
Boston
MA
USA


Yan Wu
Division of Gastroenterology, Department of Medicine
Beth Israel Deaconess Medical Center, Harvard Medical School
Boston
MA
USA


Yoshito Akagi
Department of Surgery
Kurume University
Kurume
Japan




Advertisement


Related Journals



Related Books



Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science